ATE310803T1 - Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten - Google Patents

Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten

Info

Publication number
ATE310803T1
ATE310803T1 AT95937405T AT95937405T ATE310803T1 AT E310803 T1 ATE310803 T1 AT E310803T1 AT 95937405 T AT95937405 T AT 95937405T AT 95937405 T AT95937405 T AT 95937405T AT E310803 T1 ATE310803 T1 AT E310803T1
Authority
AT
Austria
Prior art keywords
enteric
vaccines
heliobacter
acting
contain
Prior art date
Application number
AT95937405T
Other languages
English (en)
Inventor
John L Pace
Richard I Walker
Steven M Frey
Original Assignee
Antex Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/538,544 external-priority patent/US5897475A/en
Application filed by Antex Biolog Inc filed Critical Antex Biolog Inc
Application granted granted Critical
Publication of ATE310803T1 publication Critical patent/ATE310803T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/045—Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/25—Shigella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/802—Antibody or antigen-binding fragment thereof that binds gram-positive bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT95937405T 1994-10-05 1995-10-04 Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten ATE310803T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31840994A 1994-10-05 1994-10-05
US08/538,544 US5897475A (en) 1994-10-05 1995-10-03 Vaccines comprising enhanced antigenic helicobacter spp.
PCT/US1995/012986 WO1996011257A1 (en) 1994-10-05 1995-10-04 Methods for producing enhanced antigenic helicobacter sp. and vaccines comprising same

Publications (1)

Publication Number Publication Date
ATE310803T1 true ATE310803T1 (de) 2005-12-15

Family

ID=26981468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95937405T ATE310803T1 (de) 1994-10-05 1995-10-04 Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten

Country Status (20)

Country Link
US (1) US6051416A (de)
EP (1) EP0792347B1 (de)
JP (1) JP3635580B2 (de)
AT (1) ATE310803T1 (de)
AU (1) AU704348B2 (de)
BR (1) BR9509275A (de)
CA (1) CA2202029A1 (de)
CZ (1) CZ104297A3 (de)
DE (1) DE69534635T2 (de)
DK (1) DK0792347T3 (de)
ES (1) ES2255064T3 (de)
FI (1) FI971402A7 (de)
HU (1) HUT77574A (de)
IL (1) IL115522A0 (de)
MX (1) MX9702432A (de)
NO (1) NO971518L (de)
NZ (1) NZ295877A (de)
PL (1) PL183039B1 (de)
SG (1) SG90030A1 (de)
WO (1) WO1996011257A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709656B1 (en) * 1996-06-10 2004-03-23 Thomas Boren Helicobacter pylori adhesin binding group antigen
US6087128A (en) * 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
BR0015145A (pt) * 1999-10-29 2002-07-16 Wakamoto Pharma Co Ltd Anticorpo monoclonal, hibridoma, método de imunoensaio e kit para diagnose
TWI237695B (en) * 1999-12-14 2005-08-11 Joy Biomedical Corp Helicobacter pylori antigens in blood
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
JP2004077318A (ja) * 2002-08-20 2004-03-11 Uchiyama Mfg Corp 磁気エンコーダ
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923801A (en) * 1987-04-13 1990-05-08 The University Of Virginia Alumni Patents Foundation Compositions and methods for the enrichment and isolation of Campylobacter pylori and related organisms from biological specimens and the environment
US5459041A (en) * 1988-02-18 1995-10-17 Enteric Research Laboratories, Inc. Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection
US5262156A (en) * 1991-08-12 1993-11-16 Hycor Biomedical, Inc. Antigenic compositions and their use for the detection of Helicobacter pylori
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
WO1993022423A1 (en) * 1992-04-29 1993-11-11 Microcarb Inc. Nutrient phospholipids for pathogenic bacteria
US5403924A (en) * 1992-10-13 1995-04-04 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration
EP0716613B1 (de) * 1993-07-27 2003-07-09 Csl Limited Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
US5434253A (en) * 1994-03-21 1995-07-18 Vanderbilt University DNA encoding Helicobacter pylori recombinase
US5610060A (en) * 1994-06-24 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Isolated Helicobacter hepaticus
BR9509276A (pt) * 1994-10-05 1997-11-18 Antex Biolog Inc Processos para produzir uma bactéria entérica testar um agente antimicrobiano potencial detectar anticorpos de um hospedeiro para bactéria enterica e bactéria enterica em um animal ou amostra biologica deste produzir anticorpos antibacterianos e estimular uma imuno-resposta em um animal bactéria entérica tendo propriedades antigênicas aumentadas vacina e estojo de teste diagnostico para detectar um hospediro de anticorpos para bacteria enterica ou para detectar bactéria enterica
US5679564A (en) * 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
US5527678A (en) * 1994-10-21 1996-06-18 Vanderbilt University CagB and CagC genes of helicobacter pylori and related compositions

Also Published As

Publication number Publication date
JPH10507346A (ja) 1998-07-21
DE69534635T2 (de) 2006-09-21
PL319583A1 (en) 1997-08-18
AU704348B2 (en) 1999-04-22
JP3635580B2 (ja) 2005-04-06
US6051416A (en) 2000-04-18
EP0792347A4 (de) 1999-07-21
MX9702432A (es) 1998-05-31
AU3952795A (en) 1996-05-02
IL115522A0 (en) 1996-06-18
FI971402A0 (fi) 1997-04-04
BR9509275A (pt) 1997-12-23
ES2255064T3 (es) 2006-06-16
DE69534635D1 (de) 2005-12-29
EP0792347B1 (de) 2005-11-23
FI971402L (fi) 1997-06-04
HUT77574A (hu) 1998-06-29
WO1996011257A1 (en) 1996-04-18
PL183039B1 (pl) 2002-05-31
SG90030A1 (en) 2002-07-23
NZ295877A (en) 1999-03-29
NO971518D0 (no) 1997-04-03
CZ104297A3 (en) 1997-11-12
EP0792347A1 (de) 1997-09-03
FI971402A7 (fi) 1997-06-04
DK0792347T3 (da) 2006-04-03
CA2202029A1 (en) 1996-04-18
NO971518L (no) 1997-06-03

Similar Documents

Publication Publication Date Title
BR9813930A (pt) antìgeno neisserial
DE122007000082I1 (de) Verfahren für die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren
DE3889129D1 (de) Methode zum Modifizieren des Nebenproduktes eines Abgassbehandlungsprozesses.
NZ532665A (en) Neisseria meningitidis antigens and compositions
NO960839L (no) Bakterieeksporterte proteiner og acellulære vaksiner som er basert på disse
ES500567A0 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
IL123467A0 (en) Methods and compositions for the selective modification of nucleic acids
ATE355382T1 (de) Verfahren zur fermentativen herstellung von l- threonine
DE69534635D1 (de) Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten
DE69408135D1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
SG48816A1 (en) Gonococcal anti-idiotypic antibodies and methods and compositions using them
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
DE60330549D1 (de) Zur desinfektion von helicobacter pylori befähigter käse
ATE432360T1 (de) Deletierte sequenzen in m. bovis bcg / m. bovis oder m. tuberculosis, verfahren zur erkennung von mycobakterien mit diesen sequenzen und vakzine
PT95789A (pt) Metodo para isolamento e purificacao de factores antigenicos da bordetella pertussis
DE69835376D1 (de) Verfahren zum auffinden von verbindungen zur vorbeugung von infektion oder pathogenizität
EP0090660A3 (de) Neisseria Gonorrhöe Vakzin
MX9702431A (es) Metodos para producir bacterias entericas antigenicas mejoradas y vacunas que comprenden las mismas.
DE3672998D1 (de) Verfahren zum testen von dampfsterilisatoren sowie vorrichtung zur durchfuehrung des verfahrens.
DE69413952D1 (de) Extraktion von zellgebundenem protein von bordetella
DE59008875D1 (de) Verfahren zur Dekontamination mycoplasmenhaltiger Zellkulturen.
DK0774119T3 (da) Oligomere bæremolekyler med på defineret måde indföjede markeringsgrupper og haptener
MX9802809A (es) Ureasa para el tratamiento de infecciones de helicobacter pylori.
ES2192686T3 (es) Composicion farmaceutica, que comprende proteinas de complemento, para el tratamiento de infecciones por helicobacter y un metodo para la preparacion de la composicion.
DE69433851D1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0792347

Country of ref document: EP

REN Ceased due to non-payment of the annual fee